



COPY OF PAPERS  
ORIGINALLY FILED

Op/1644  
#7

Please type and sign (+) inside this box → **+**

PTO/SB/21 (08-00)

Approved for use through 10/31/02. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	09/990,205	
	Filing Date	November 20, 2001	
	First Named Inventor	Kenneth A. FOON	
	Group Art Unit	1644	
	Examiner Name	To Be Assigned	
Total Number Of Pages In This Submission	10	Attorney Docket No.	304142000501

**RECEIVED**  
MAY 24 2002  
TECH CENTER 1600/2900

**ENCLOSURES (check all that apply)**

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declarations	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): - Form PTO-1449 (6 pages) - Return Receipt Postcard
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement (3 pages)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

**SIGNATURE OF APPLICANT, ATTORNEY OR AGENT**


Firm or Individual Name	Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304
Signature	<i>Catherine M. Polizzi</i>
Date	May 7, 2002

**CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on May 7, 2002.

*Mei Leung*  
Mei Leung

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



COPY OF PAPERS  
ORIGINALLY FILED

PATENT  
Docket No. 304142000501

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231, on May 7, 2002.

  
Mei Leung

RECEIVED

MAY 24 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

In the application of:

Kenneth A. FOON and  
Malaya CHATTERJEE

Serial No.: 09/990,205

Filing Date: November 20, 2001

For: METHODS AND COMPOSITIONS FOR  
THE TREATMENT OF PSORIASIS

Examiner: To Be Assigned

Group Art Unit: 1644

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 09/192,838, filed November 16, 1998 (now U.S. Patent No. 6,355,244 B1), and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. § 1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of is enclosed.
  - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of is enclosed.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 304142000501. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: May 7, 2002

Respectfully submitted,

By: Catherine M. Polizzi  
Catherine M. Polizzi  
Registration No. 40,130

Morrison & Foerster LLP  
755 Page Mill Road  
Palo Alto, California 94304-1018  
Telephone: (650) 813-5651  
Facsimile: (650) 494-0792

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 304142000501

Application Number 09/990,205

Applicant

Kenneth A. FOON and Malaya CHATTERJEE

Filing Date November 20, 2001

Group Art Unit 1644

Mailing Date May 7, 2002

RECEIVED

MAY 24 2002

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	03/13/84	4,436,728	Ribi et al.			
	2.	02/23/88	4,726,947	Shimada et al.			
	3.	01/15/91	4,985,434	Secrist, III et al.			
	4.	04/16/91	5,008,265	Secrist, III et al.			
	5.	04/16/91	5,008,270	Secrist, III et al.			
	6.	10/01/91	5,053,224	Koprowski et al.			
	7.	10/15/91	5,057,540	Kensil et al.			
	8.	12/31/91	5,077,284	Loria et al.			
	9.	04/07/92	5,102,663	Livingston et al.			
	10.	08/25/92	5,141,742	Brown et al.			
	11.	12/15/92	5,171,568	Burke et al.			
	12.	05/03/94	5,308,614	Hakomori			
	13.	07/19/94	5,330,977	Tubaro et al.			
	14.	04/18/95	5,407,684	Loria et al.			
	15.	03/19/96	5,500,215	Hakomori			
	16.	06/25/96	5,529,922	Chapman et al.			
	17.	11/05/96	5,571,900	Wiegand et al.			
	18.	03/18/97	5,612,030	Chatterjee et al.			
	19.	08/05/97	5,653,977	Saleh			

COPY OF PAPERS  
ORIGINALLY FILED

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	20.	03/22/90	WO 90/02809	PCT			
	21.	05/16/90	0 368 131 B1	EPO			English Abstract

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 304142000501

Application Number 09/990,205

Applicant

Kenneth A. FOON and Malaya CHATTERJEE

Filing Date November 20, 2001

Group Art Unit 1644

Mailing Date May 7, 2002

RECEIVED

MAY 24 2002

TECH CENTER 1600/2900

COPY OF PAPERS  
ORIGINALLY FILED

22.	09/20/90	WO 90/10631	PCT				
23.	07/11/91	WO 91/09603	PCT				
24.	08/08/91	WO 91/11718	PCT				
25.	08/28/91	0 443 518 A2,A3	EPO				
26.	11/14/91	WO 91/16924	PCT				
27.	01/23/92	WO 92/01047	PCT				
28.	10/01/92	WO 92/16231	PCT				
29.	11/12/92	WO 92/19266	PCT				
30.	05/27/93	WO 93/10134	PCT				
31.	10/28/93	WO 93/21187	PCT				
32.	05/24/94	JP 6 145069	Japan			English Abstract	
33.	06/23/94	WO 94/13804	PCT				
34.	08/04/94	WO 94/16731	PCT				
35.	01/12/95	WO 95/01355	PCT				
36.	02/16/95	WO 95/04548	PCT				
37.	07/05/95	0 661 061 A2,A3	EPO				
38.	10/12/95	WO 95/26718	PCT				
39.	05/07/96	BE 1008391	Belgium			English Abstract	
40.	07/04/96	WO 96/20219	PCT				
41.	07/04/96	WO 96/20277	PCT				
42.	07/25/96	WO 96/22373	PCT				
43.	06/26/97	WO 97/22694	PCT				

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	44.	<i>Animal Cell Culture: A Practical Approach</i> , R.I. Freshney, ed., IRL Press, 1987 (Table of Contents).
	45.	<i>Antibodies: A Laboratory Manual</i> Ed Harlow, David Lane, eds., Cold Spring Harbor Laboratory, New York, 1988 (Table of Contents).
	46.	Beardsley, Tim, "Crabshoot [sic]. Manufacturers gamble on cancer vaccines — again" <i>Scientific American</i> p.102, September, 1994.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 304142000501

Application Number 09/990,205

Applicant

Kenneth A. FOON and Malaya CHATTERJEE

Filing Date November 20, 2001

Group Art Unit 1644

Mailing Date May 7, 2002


COPY OF PAPERS  
ORIGINALLY FILED

- |     |  |
|-----|--|
| 47. | Bhattacharya-Chatterjee et al., "Idiotypic vaccines against human T cell acute lymphoblastic leukemia. I. Generation and characterization of biologically active monoclonal anti-idiotypes" <i>J. Immunol.</i> 139:1354-1360, 1987.                              |
| 48. | <i>Bioworld Today</i> , pp. 001-006, Sept. 29, 1997.   |
| 49. | Bird et al., "Single-chain antigen-binding proteins" <i>Science</i> 242:423-426, 1988.   |
| 50. | "Cell Culture" <i>Methods in Enzymology</i> , Volume LVIII, William B. Jacoby, Ira H. Pastan, eds., Academic Press, 1979 (Table of Contents).  |
| 51. | Chattopadhyay et al., "Murine monoclonal anti-idiotypic antibody breaks unresponsiveness and induces a specific antibody response to human melanoma-associated proteoglycan antigen in cynomolgus monkeys" <i>Proc. Natl. Acad. Sci. USA</i> 89:2684-2688, 1992. |
| 52. | Cheresh et al., "Biosynthesis and expression of the disialoganglioside G <sub>D2</sub> , a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytotoxicity" <i>Cancer Res.</i> 46:5112-5118, 1996.                            |
| 53. | Cheung et al., "Disialoganglioside G <sub>D2</sub> anti-idiotypic monoclonal antibodies" <i>Int. J. Cancer</i> 54:499-505, 1993.   |
| 54. | Cheung et al., "Ganglioside G <sub>D2</sub> specific monoclonal antibody 3F8. A Phase I study in patients with neuroblastoma and malignant melanoma" <i>J. Clin. Oncol.</i> 5:1430-1440, 1987.   |
| 55. | Conry et al., "A carcinoembryonic antigen polynucleotide vaccine for human clinical use" <i>Cancer Gene Ther.</i> 2:33-38, 1995.   |
| 56. | <i>Current Protocols in Immunology</i> , Volume 1, Supplement 28, John E. Coligan et al., eds., John Wiley & Sons, Inc., 1998 (Table of Contents).   |
| 57. | <i>Current Protocols in Molecular Biology</i> , Volume 1, Supplement 30, 39, 40, Frederick M. Ausubel et al., eds., John Wiley & Sons, Inc., 1995 (Table of Contents).   |
| 58. | Dabelsteen et al., "Cell surface glycosylation patterns in psoriasis" <i>APMIS</i> 98:221-228, 1990.   |
| 59. | Denton et al., "Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody" <i>Int. J. Cancer</i> 57:10-14, 1994.  |
| 60. | Fiedler et al., "High-level production and long-term storage of engineered antibodies in transgenic tobacco seeds" <i>Biotechnology</i> 13:1090-1093, 1995.  |
| 61. | "Gene transfer vectors for mammalian cells" <i>Current Communications in Molecular Biology</i> , Jeffrey H. Miller, Michele P. Calos, eds., Cold Spring Harbor Laboratory, 1987 (Table of Contents).   |
| 62. | Hamilton et al., "Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography" <i>Int. J. Cancer</i> 53:566-573, 1993.  |
| 63. | Hastings et al., "Production and characterization of a murine/human chimeric anti-idiotypic antibody that mimics ganglioside" <i>Cancer Res.</i> 52:1681-1686, 1992.   |
| 64. | Hawkins et al., "A genetic approach to idiotype vaccination" <i>J. Immunother.</i> 14:273-278, 1993.   |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



MAY 24 2002

PTO/SB/08 (2-92)

Sheet 4 of 5

TECH CENTER 1600/2000

Form PTO-1449

Docket Number 304142000501

Number 09/990,205

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Kenneth A. FOON and Malaya CHATTERJEE

Filing Date November 20, 2001

Group Art Unit 1644

Mailing Date May 7, 2002

COPY OF PAPERS  
ORIGINALLY FILED

- |     |   |
|-----|---|
| 65. | Heidenheim et al., "CDw60, which identifies the acetylated form of G <sub>D3</sub> gangliosides, is strongly expressed in human basal cell carcinoma" <i>Br. J. Dermatol.</i> 133:392-397, 1995.  |
| 66. | Helling et al., "Ganglioside conjugate vaccines. Immunotherapy against tumors of neuroectodermal origin" <i>Mol. &amp; Chem. Neuropath.</i> 21:299-309, 1994.   |
| 67. | Herlyn et al., "Cloned antigens and antiidiotypes" <i>Hybridoma</i> 14:159-166, 1995.   |
| 68. | "Immunochemistry and molecular immunology" <i>Weir's Handbook of Experimental Immunology</i> Volume 1, Donald M. Weir, Caroline Blackwell, eds., 1996 (Table of Contents).  |
| 69. | Kanda et al., "Both V <sub>H</sub> and V <sub>L</sub> regions contribute to the antigenicity of anti-idiotypic antibody that mimics melanoma associated ganglioside GM <sub>3</sub> " <i>Cell Biophysics</i> Vols. 24,25:65-74, 1994.   |
| 70. | Liang et al., "Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction" <i>Science</i> 257:967-971, 1992.  |
| 71. | Liang et al., "Recent advances in differential display" <i>Curr. Opin. Immunol.</i> 7:274-280, 1995.  |
| 72. | Livingston et al., "GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3" <i>Vaccine</i> 11:1199-1204, 1993.  |
| 73. | Livingston, Philip O., "Approaches to augmenting the immunogenicity of melanoma gangliosides: From whole melanoma cells to ganglioside-KLH conjugate vaccines" <i>Immunol. Review</i> 145:147-166, 1995.  |
| 74. | Livingston, Philip O., "Construction of cancer vaccines with carbohydrate and protein (peptide) tumor antigens" <i>Curr. Opin. Immunol.</i> 4:624-629, 1992.  |
| 75. | Mackett et al., "The construction and characterisation of vaccinia virus recombinants expressing foreign genes" <i>DNA Cloning, Vol. 11: A Practical Approach</i> Chapter 7, pp. 191-211.   |
| 76. | Marks et al., "Phage libraries - a new route to clinically useful antibodies" <i>New Engl. J. Med.</i> 335:730-733, 1996.   |
| 77. | McGuinness et al., "Phage diabody repertoires for selection of large numbers of bispecific antibody fragments" <i>Nature Biotechnol.</i> 14:1149-1154, 1996.  |
| 78. | Mittelman et al., "Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma" <i>Proc. Natl. Acad. Sci. USA</i> 89:466-470, 1992.                                |
| 79. | Mittelman et al., "Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23" <i>Cancer Res.</i> 54:415-421, 1994. |
| 80. | <i>Molecular Cloning: A Laboratory Manual</i> , Second Edition, J. Sambrook et al., eds., Cold Spring Harbor Laboratory Press, 1989 (Table of Contents).  |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)  
pa-685766

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 304142000501

Application Number 09/990,269

Applicant

Kenneth A. FOON and Malaya CHATTERJEE

Filing Date November 20, 2001

Group Art Unit 1644

Mailing Date May 7, 2002

- |     |  |
|-----|--|
| 81. | Moss, Bernard, "Vaccinia virus: A tool for research and vaccine development" <i>Science</i> 252:1662-1667, 1991.   |
| 82. | O'Boyle et al., "Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn" <i>Cancer Res.</i> 52:5663-5667, 1992. |
| 83. | Offner et al., "Lymphocyte stimulation by gangliosides, cerebroside and basic protein in juvenile rheumatoid arthritis" <i>J. Clin. Lab. Immunol.</i> 6:35-37, 1981.   |
| 84. | <i>Oligonucleotide Synthesis. A Practical Approach</i> , M.J. Gait, ed., IRL Press 1984 (Table of Contents).   |
| 85. | Paller et al., "Absence of a stratum corneum antigen in disorders of epidermal cell proliferation: Detection with an anti-ganglioside G <sub>M3</sub> antibody" <i>J. Invest. Dermatol.</i> 92:240-246, 1989.  |
| 86. | Paller et al., "Ganglioside G <sub>M3</sub> inhibits the proliferation of cultured keratinocytes" <i>J. Invest. Dermatol.</i> 100:841-845, 1993.   |
| 87. | Pardoll, Drew, "New strategies for active immunotherapy with genetically engineered tumor cells" <i>Curr. Opin. Immunol.</i> 4:619-623, 1992.  |
| 88. | Progenics Pharmaceuticals, Inc. Prospectus for sale of 2,000,000 shares of Common Stock subject to completion, dated October 30, 1996.   |
| 89. | <i>Remington's Pharmaceutical Sciences</i> , 18th Edition, Alfonso R. Gennaro, ed., Mack Publishing Co., PA, 1990 (Table of Contents).   |
| 90. | Saleh et al., "Generation of a human anti-idiotypic antibody that mimics the GD2 antigen" <i>J. Immunol.</i> 151:3390-3398, 1993.  |
| 91. | Samonigg et al., "Immune response to tumor antigens in a patient with colorectal cancer after immunization with anti-idiotypic antibody" <i>Clin. Immunol. Immunopathol.</i> 65:271-277, 1992.                 |
| 92. | Skov et al., "Lesional psoriatic T cells contain the capacity to induce a T cell activation molecule CDw60 on normal keratinocytes" <i>Am. J. Pathol.</i> 150:675-683, 1997.                                   |
| 93. | Sunday, Mary E., "Differential display RT-PCR for identifying novel gene expression in the lung" <i>Am. J. Physiol.</i> 269:L273-L284, 1995.   |
| 94. | Takahashi et al., "Induction of CD8 <sup>+</sup> cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs" <i>Nature</i> 344:873-875, 1990.  |
| 95. | Tang et al., "Genetic immunization is a simple method for eliciting an immune response" <i>Nature</i> 356:152-154, 1992.   |
| 96. | <i>The Merck Manual of Diagnosis and Therapy</i> , Vol. 17, Section 10, Chapter 117, Whitehouse Station, NJ, 1999.   |
| 97. | <i>The Polymerase Chain Reaction</i> , Kary B. Mullis et al., eds., Birkhäuser, 1994 (Table of Contents).  |
| 98. | Yamamoto et al., "Anti-idiotypic monoclonal antibody carrying the internal image of ganglioside GM3" <i>J. Natl. Cancer Inst.</i> 82:1757-1760, 1990.  |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.